Fresh Tracks Therapeutics, Inc.
FRTX evidence brief
What we can confirm
- BioSniper Score:
- 4.3 / 10
- Lead Asset:
- frtx-02 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for FRTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
frtx-02 (Phase 1)
Next Catalyst
—
Tracking 2 pipeline candidates for Fresh Tracks Therapeutics, Inc..
Run Fresh Tracks Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Fresh Tracks Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is Fresh Tracks Therapeutics, Inc.'s lead drug candidate?
Fresh Tracks Therapeutics, Inc.'s most advanced tracked candidate is frtx-02 (Phase 1) for Autoimmune and inflammatory diseases.
Who is the CEO of Fresh Tracks Therapeutics, Inc.?
Fresh Tracks Therapeutics is the chief executive officer of Fresh Tracks Therapeutics, Inc. (FRTX).
What therapeutic areas does Fresh Tracks Therapeutics, Inc. focus on?
Fresh Tracks Therapeutics, Inc. develops therapies across Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.